Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Mazdutide
Mezdutide, also known as mazdutide or OXM3, is a dual agonist peptide that targets both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range2.5 mcgWeeks 1-4
Recorded example with no verified study backing; shown for amount literacy only.
- Low-mid range5 mcgWeeks 5-8+
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range2.5 mgWeeks 1-4
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Mezdutide
What published studies and recent community write-ups report about amounts, timing and course length. 7 clinical and 2 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical7 rows | |||||
| Chinese prescribing information (Xinermei), weight managementAdults in China with obesity (BMI 28 or more) or overweight (BMI 24 or more) plus a weight-related condition | 2 mg weeks 1-4, 4 mg weeks 5-8, then 4 mg or 6 mg maintenance | Once weekly, any time of day, with or without food | Subcutaneous, abdomen, from 2 mg, 4 mg and 6 mg prefilled pens (0.5 mL each) | Continuous; the step to 6 mg is taken only after at least 4 weeks on 4 mgNone; if 6 mg is not tolerated the label describes returning to 4 mg | Innovent Biologics2025 |
| The label approved on 24 June 2025 gives detailed missed-dose rules: inject within 2 days late and keep the schedule, within 2-7 days inject and reset the weekly day, 7-21 days late drop back one dose level and re-titrate, and beyond 21 days restart at 2 mg. It reports peak levels 7-28 hours after injection, steady state after 4 weekly doses and an elimination half-life of roughly 10 days, and notes that only three trial participants were 65 or older. | |||||
| Phase 3 GLORY-1 (obesity or overweight, China)610 Chinese adults aged 18-75 with BMI 28 or more, or 24 to under 28 with a weight-related condition | 4 mg (2 mg for weeks 1-4, then 4 mg) or 6 mg (2 mg weeks 1-4, 4 mg weeks 5-8, then 6 mg) | Once weekly | Subcutaneous | 48 weeksNone | New England Journal of Medicine2025 |
| Weight fell 10.1% and 12.6% at week 32 (the primary endpoint) and 11.0% and 14.0% at week 48 on 4 mg and 6 mg, against a 0.3% gain on placebo, with half of the 6 mg group losing at least 15%. Gastrointestinal events were the most common adverse events but discontinuation for adverse events was rare (1.5%, 0.5% and 1.0% on 4 mg, 6 mg and placebo). | |||||
| Phase 3 GLORY-2 (9 mg, obesity with BMI 30 or more)461 Chinese adults with BMI of 30 or more, 16% with type 2 diabetes, mean age 34 | 9 mg maintenance, reached by stepwise escalation | Once weekly | Subcutaneous | 60 weeksNone | JAMA2026 |
| Mean weight change was 16.7% versus 1.5% on placebo at 60 weeks, and 84% of the mazdutide group lost at least 5%. The price of the higher dose was vomiting in 53%, nausea in 47% and diarrhea in 39% of participants, mostly mild to moderate, with 2.9% stopping treatment for adverse events. | |||||
| US phase 2 dose-ranging trial (up to 16 mg)179 US adults with obesity, or overweight plus a comorbidity, without type 2 diabetes | 3 mg held from week 4 to week 32 then 6 mg; or 10 mg; or 16 mg | Once weekly | Subcutaneous | 48 weeks (primary endpoint at 32 weeks)None | The Lancet Diabetes & Endocrinology2026 |
| At 32 weeks weight fell 7.3%, 15.6% and 18.1% on the 3-6 mg, 10 mg and 16 mg arms against 0.9% on placebo, with further loss by week 48. Gastrointestinal events led to discontinuation in 20% of the 16 mg group, so the doses above 9 mg bought extra weight loss at a clear tolerability cost. | |||||
| Phase 2 obesity trial, three dose ladders248 Chinese adults who were overweight with hyperphagia or a comorbidity, or had obesity | 3 mg (1.5 mg weeks 1-4, then 3 mg), 4.5 mg (1.5, 3, then 4.5 mg every 4 weeks) or 6 mg (2, 4, then 6 mg every 4 weeks) | Once weekly | Subcutaneous prefilled device | 24 weeks, then 12 weeks off-treatment follow-up12-week post-treatment observation built into the design | Nature Communications2023 |
| Weight fell 6.7%, 10.4% and 11.3% at 24 weeks on 3, 4.5 and 6 mg versus a 1.0% gain on placebo. Diarrhea, nausea and upper respiratory infections were the most common events; this interim analysis fixed the 2-4-6 mg ladder later carried into the phase 3 program. | |||||
| Phase 3 DREAMS-1 (type 2 diabetes, monotherapy)320 Chinese adults with type 2 diabetes controlled inadequately by diet and exercise (mean HbA1c 8.2%) | 4 mg or 6 mg | Once weekly | Subcutaneous | 24 weeks placebo-controlled, then 24 weeks of extended treatmentNone | Nature2025 |
| HbA1c fell 1.57 and 2.15 percentage points on 4 mg and 6 mg against 0.14 on placebo, with weight down 5.6% and 7.8% versus 1.3%. Diarrhea, decreased appetite and nausea were the most common adverse events, in line with other incretin drugs. | |||||
| Phase 3 DREAMS-2 (type 2 diabetes, versus dulaglutide)731 Chinese adults with type 2 diabetes on oral glucose-lowering drugs | 4 mg or 6 mg (comparator dulaglutide 1.5 mg) | Once weekly | Subcutaneous | 28 weeksNone | Nature2025 |
| Both doses beat dulaglutide 1.5 mg on HbA1c (differences of 0.24 and 0.30 percentage points) and by a wider margin on weight (3.8% and 5.8% more loss). Gastrointestinal adverse events were more frequent with mazdutide than with dulaglutide. | |||||
| Community-reported2 rows | |||||
| Research-vial reconstitution math | 3-9 mg (3 mg described as a common starting point) | Once weekly | Subcutaneous from a 10 mg lyophilized vial reconstituted with 2 mL bacteriostatic water (5 mg/mL) | Not specifiedNone described | Community resource2026 |
| This 2026 calculator page says the community standard is 2 mL of water per 10 mg vial, so 3 mg is 60 units on a U-100 syringe and 6 mg would exceed a single syringe draw. It states that community access runs through Chinese research suppliers and that the doses are borrowed from the trial arms rather than any label outside China. | |||||
| Vendor education page restating trial doses | 4, 6 or 9 mg weekly after stepwise escalation (the published phase 3 doses) | Once weekly | Subcutaneous | 48-60 weeks in the trials citedNone described | Community resource2026 |
| A peptide vendor's 2026 page deliberately refuses to publish a schedule, pointing out that the only approved label is Chinese and that research-grade powder adds reconstitution and identity errors on top of an unverified product. It frames the GLORY-1 and GLORY-2 numbers as evidence about a studied population rather than instructions. | |||||
How a course is commonly described
- Weeks 1-4: 2 mgClinical
Every phase 3 trial and the Chinese label start at 2 mg once weekly and hold it for four weeks while the drug reaches steady state. Nausea, diarrhea and reduced appetite cluster in this period, and the label allows any time of day without regard to meals.
- Weeks 5-8: 4 mgClinical
The first step up, which is also the lower maintenance dose. In GLORY-1 the 4 mg arm lost 10.1% of body weight by week 32 and 11.0% by week 48 with the lowest rate of gastrointestinal complaints among the active arms.
- Week 9 onward: 4 mg or 6 mg maintenanceClinical
The label leaves the choice between 4 mg and 6 mg to the prescriber, with 6 mg only after at least four weeks on 4 mg and a step back to 4 mg if it is not tolerated. The 6 mg arm of GLORY-1 reached 14.0% weight loss at 48 weeks and DREAMS-1 continued 4 mg and 6 mg for 48 weeks in people with diabetes.
- Higher doses in trials onlyClinical
GLORY-2 escalated to 9 mg and held it for 60 weeks, producing 16.7% weight loss but vomiting in more than half of participants, and the US phase 2 trial tested 10 mg and 16 mg with one in five dropping out of the 16 mg arm. Neither dose is on any label.
- Missed doses and stoppingClinical
The Chinese label is the only source with missed-dose rules: catch up within 7 days, drop one level if 7-21 days have passed, and restart titration from 2 mg after more than 21 days. No trial describes a taper, and the phase 2 study's 12-week off-treatment follow-up is the only published look at what happens after stopping.
- Mazdutide is approved only in China. Everywhere else it is investigational, so the 2-4-6 mg ladder is a trial and label schedule from one country, not a global dosing recommendation, and the 9, 10 and 16 mg arms exist only inside clinical trials.
- Gastrointestinal side effects scale steeply with dose: discontinuation for adverse events was about 1% at 4-6 mg in GLORY-1, 2.9% at 9 mg in GLORY-2 and 20% at 16 mg in the US phase 2 trial. The label's missed-dose rules exist because restarting at a maintenance dose after a long gap brings those effects back.
- Trial participants used manufacturer-supplied prefilled pens under medical supervision. Powder sold online as mazdutide is unregulated, and PubChem's own structure for the compound differs from the registered sequence by one serine, which shows how easily identity details drift outside the regulated supply chain.
Sources for this section (11)
- Mazdutide Injection (Xinermei) Chinese prescribing information
- Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
- Mazdutide: First Approval
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial
- Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
- Mazdutide versus placebo in Chinese adults with type 2 diabetes
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Plus 2 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Mazdutide, spelled Mezdutide on this site, is a once-weekly injectable analog of the gut hormone oxyntomodulin that activates both the GLP-1 and glucagon receptors; it was designed under the development code LY3305677 and licensed to Innovent Biologics for China under the code IBI362. The 34-residue peptide carries an Aib at position 2, a C-terminal amide and a 20-carbon fatty diacid on lysine 20, giving a half-life of about 10 days. China's regulator approved it in June 2025 as Xinermei for chronic weight management in adults with a BMI of 28 or more (or 24 or more with a weight-related condition), with a type 2 diabetes approval following in September 2025; it is not approved by the FDA or EMA, and a US phase 2 trial testing doses up to 16 mg was published in 2026.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Preclinical Studies
Research on Mezdutide in animal models
- 2
Clinical Trials
Human clinical trial results and findings
- 3
Advancements in Metabolic Health
Future applications in metabolic disease management
- 4
Innovation in Peptide-Based Therapies
The role of Mezdutide in advancing peptide therapeutics
- 5
Improving Quality of Life
Impact on patient well-being and health outcomes
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Preclinical Studies
Research on Mezdutide in animal models
- Not graded
Clinical Trials
Human clinical trial results and findings
Amounts recorded for Mazdutide
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Weeks 1-4Sign in for schedule, duration and source context.2.5 mcg
- 2Weeks 5-8+Sign in for schedule, duration and source context.5 mcg
- 3Weeks 1-4Sign in for schedule, duration and source context.2.5 mg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys(C20 diacid-gamma-Glu-AEEA-AEEA)-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2
Also listed as
Mazdutide, IBI362, IBI-362, LY3305677, LY-3305677, Xinermei (Chinese brand name), UNII MB76Z4IBZ5, GTPL13924
InChIKey
XRBYWQZGSZWYEJ-HMQIFOERSA-N
IUPAC name
20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.